Moderna personalized mRNA cancer vaccine succeeds in Phase 3 trial
thedealdirector · x · 2026-08-20
Moderna and Merck announced that a personalized mRNA cancer vaccine succeeded in a Phase 3 melanoma trial, marking the first late-stage win for an individualized mRNA cancer therapy. Moderna's stock surged about 90% on the news.
Related event: Moderna's Personalized mRNA Cancer Therapy Succeeds in Phase III Trial(5 posts)→
More from Research
- DepthFirst releases dfbench for defensive cyber security evals — andreamichi · 2026-08-20
- IBM study: Rephrasing questions swings LLM benchmark scores by up to 74.7 points — rohanpaul_ai · 2026-08-20
- Zero-backend WebGL app turns LLM outputs into 3D historical maps — Silent-Assumption292 · 2026-08-20
- Joseph Suarez Shares Reinforcement Learning Resources — jsuarez · 2026-08-20
- Jeff Dean on leaving Google: excited to focus on a mission at a small company — firstadopter · 2026-08-20
- RAM Score Proposed to Quantify Relative HuggingFace Model Adoption — natolambert · 2026-08-20